ClearPoint Neuro (CLPT) Projected to Announce Quarterly Earnings on Wednesday

ClearPoint Neuro (NASDAQ:CLPT) is projected to release its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect ClearPoint Neuro to post earnings of ($0.32) per share and revenue of $12.30 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.09). ClearPoint Neuro had a negative return on equity of 188.09% and a negative net margin of 81.76%. The firm had revenue of $10.88 million during the quarter, compared to analyst estimates of $12.73 million. During the same quarter in the prior year, the firm earned ($0.21) EPS. On average, analysts expect ClearPoint Neuro to post ($1.22) EPS for the current fiscal year and ($1.16) EPS for the next fiscal year.

ClearPoint Neuro Stock Performance

NASDAQ:CLPT opened at $9.14 on Monday. The stock has a market cap of $278.77 million, a price-to-earnings ratio of -7.75 and a beta of 1.29. ClearPoint Neuro has a one year low of $8.27 and a one year high of $27.27. The company has a debt-to-equity ratio of 4.66, a quick ratio of 3.89 and a current ratio of 4.74. The business’s 50-day simple moving average is $13.01 and its 200 day simple moving average is $13.50.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CLPT shares. Stifel Nicolaus set a $22.00 price objective on ClearPoint Neuro in a report on Tuesday, August 4th. Wall Street Zen lowered ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Lake Street Capital set a $25.00 target price on ClearPoint Neuro in a research note on Tuesday, August 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $25.67.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes platforms for minimally invasive procedures involving the brain. Its technology is designed to help physicians plan, navigate and deliver treatments with real-time magnetic resonance imaging (MRI) guidance, supporting more precise access to targeted areas of the brain.

The company’s principal product is the ClearPoint Neuro Navigation System, which uses specialized software, instruments and accessories to guide neurosurgical procedures inside an MRI scanner.